1 / 16

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE). Metastatic Breast Cancer 10% of breast cancer. 30+ patients per year in Colchester All incurable but median survival 2 to 3 years with current therapy

urbana
Download Presentation

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

  2. Metastatic Breast Cancer 10% of breast cancer. 30+ patients per year in Colchester All incurable but median survival 2 to 3 years with current therapy Endocrine Therapy Response takes up to 3 months Chemotherapy Toxic and expensive

  3. STUDY RATIONALE Novel protein BORIS discovered in WBC of Breast Cancer Patients Ongoing Study suggests that BORIS could be a Biomarker for response to treatment in Primary Breast Cancer ? Role of BORIS in monitoring response in metastatic breast cancer ? Role in predicting response Identification of other proteins in metastatic breast cancer

  4. STUDY DESIGN Endocrine Therapy: Research Bloods at baseline, 6 weeks and 12 weeks Clinical assessment, standard blood tests 6 12 Scan , Final clinical assessment 12 week Chemotherapy: Research Bloods at baseline, 3 weekly x 6 Clinical assessment, standard blood tests 3 weekly Scan, post 3 cycles, post 6 cycles Final clinical assessment post 6 cycles

  5. BIOMARKER BENEFIT Prediction of response to therapy ER/PR Monitoring of response to therapy AFP Prediction of relapse CA 125

  6. Current Status of Project Target of 30 patients Patient 31 just enrolled ( in six months) 11 endocrine, 20 chemotherapy 21 patients completed study 50% responding to treatment 50% progressing on treatment In next 3 months all samples collected and clinical responses documented

  7. Scientific Perspective • Previous study- BORIS in WBC of breast cancer patients. • Investigate BORIS in WBC of patients with metastatic breast disease. • Find a new blood biomarkers to monitor treatment efficacy.

  8. How? Blood collection Plasma Cell smears WBC Cell pellets X RBC WBC Plasma 2D gel electrophoresis Western Blot Analysis Immunocytochemistry Abundant protein depletion Western Blot Analysis 2D gel electrophoresis ?

  9. WBC Boris? Identify/quantify BORIS levels - monitor pre & during treatment New Biomarkers? Protein Profile of patients WBC Comparison of ‘normal’ versus patient- pre-treatment Comparison of patient- pre-treatment versus final treatment Identify candidate blood biomarkers

  10. Plasma/Serum markers? Currently used CEA (Carcineoembryonic antigen) CA 15.3 (Cancer Antigen breast) Candidate markers- - collaborative study with Metodiev group (Uni). Novel markers?

  11. So far…………….. BORIS? New biomarker-2D gels? Protein ID? Protein absent? V Differences in protein profile? Normal (healthy) Patient 005

  12. So far…………….. 30 patients- 15 analysed pre-treatment. Candidate novel markers? Protein ID? Normal ABS 009 ABS 008

  13. Pre-treatment Final Pre-treatment Final Patient 003 –pre-treatment v final treatment Protein ID? Protein ID?

  14. Correlation with clinical data Chemotherapy or hormone therapy? Clinical response? Metastatic disease? BORIS and/or new biomarker?

More Related